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Summary 
Substitution of pancreatic islets is a potential therapy to treat diabetes and it depends on 
reconstitution of islet’s capillary network. In this study, we addressed the question whether 
stabilization of Glucagon-Like-Peptide-1 (GLP-1) by inhibiting Dipeptidyl Peptidase-IV 
(DPP-IV) increases β-cell mass by modulating vascularization. 
Mouse or porcine donor islets were implanted under kidney capsule of diabetic mice treated 
with DPP-IV inhibitor, sitagliptin. Grafts were analyzed for insulin production, β-cell 
proliferation and vascularization. In addition, the effect of sitagliptin on sprouting and 
Vascular Endothelial Growth Factor (VEGF)-A expression was examined ex vivo. The 
cAMP response element-binding (CREB) and VEGF-A/ Vascular Endothelial Growth Factor 
Receptor (VEGFR)-2 signaling pathway leading to islet vascularization was explored. 
Sitagliptin increased mean insulin content of islet grafts and area of insulin-positive 
tissue as well as β-cell proliferation. Interestingly, sitagliptin treatment also markedly 
increased endothelial cell proliferation, microvessel density and blood flow. Finally, GLP-1 
(7-36) stimulated sprouting and VEGF expression, which was significantly enhanced by 
sitagliptin- mediated inhibition of DPP-IV. Our in vivo data demonstrate that sitagliptin 
treatment phosphorylated CREB and induced islet vascularization through VEGF-
A/VEGFR-2 signaling pathway. This study paves a new pathway for improvement of islet 
transplantation in treating diabetes mellitus. 
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 Zusammenfassung 
Der Ersatz von Langerhansschen Inselzellen stellt eine Therapiemöglichkeit des Diabetes 
Mellitus dar und hängt von der Wiederherstellung der Kapillarnetze der Inseln ab. In dieser 
Arbeit wird geprüft, ob eine Stabilisierung des Glucagon-Like-Peptide-1 (GLP-1) durch 
Inhibition der Dipeptidylpeptidase-IV (DPP-IV) eine Vergrößerung der Betazellmasse durch 
Veränderung der Vaskularisierung hervorruft. 
Von Mäusen oder Schweinen stammende Inseln wurden unter die Nierenkapsel von 
diabetischen Mäusen transplantiert. Diese Mäuse wurden mit dem DPP-IV-Inhibitor 
Sitagliptin behandelt. Die Transplantate wurden auf ihre Insulinproduktion, 
Betazellproliferation und Vaskularisierung untersucht. Zusätzlich analysiert wurden der 
Effekt des Sitagliptins auf die Angiogenese sowie die Expression von Vascular Endothelial 
Growth Factor (VEGF)-A. Die cAMP response element-binding (CREB) und VEGF-
A/Vascular Endothelial Growth Factor Receptor (VEGFR)-2-Signalwege waren darüber 
hinaus Objekt der Forschung. 
Sitagliptin führte zu einer Erhöhung des mittleren Insulingehalts der Transplantate, zu einer 
flächenmäßigen Vergrößerung des Insulin-positiven Gewebes und zu Betazellproliferation. 
Bemerkenswerterweise erhöhten sich durch die Behandlung mit Sitagliptin auch die 
Proliferation der Endothelzellen, die Kapillardichte und der Blutfluss. Schließlich wirkte 
GLP-1 stimulierend auf Angiogenese und VEGF-Expression, welche aufgrund der Inhibition 
von DPP IV durch GLP-1 signifikant verbessert wurden. 
Unsere in vivo gesammelten Daten demonstrieren, dass eine Behandlung mit Sitagliptin 
CREB phosporyliert und eine vermehrte Vaskularisierung von Langerhansschen Inseln durch 
den VEGF-A/VEGFR-2-Signalweg induziert. Diese Arbeit ebnet einen neuen Weg zu einer 
Verbesserung der Inseltransplantation in der Behandlung des Diabetes Mellitus. 
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1. Introduction 
 
1.1 Pancreas 
1.1.1Pancreas anatomy 
The pancreas serves two major functions: (i) the production of digestive enzymes, which are 
secreted by exocrine acinar cells and routed to the intestine by a branched ductal network; and 
(ii) the regulation of blood sugar, which is achieved by endocrine cells of the islets of 
Langerhans (1). The pancreas is often described as two organs in one, due to the distinct 
function and organization of its endocrine and exocrine components. In higher vertebrates, it 
might more properly be thought of as four organs, as it comprises anatomically distinct dorsal 
and ventral lobes. Referred to in humans as the tail and head, respectively, these two 
pancreatic lobes arise as thickenings along the dorsal and ventral surfaces of the posterior 
foregut, near the prospective hepatic endoderm (1). 
The bulk of the mature pancreas is comprised of acinar cells, connected to the intestine via a 
highly branched ductal tree, while islets are primarily scattered through the central regions of 
the organ. Several separate endocrine cell types comprise the islet: β -cells are the most 
prominent (50-80% of the total, depending on species) (2; 3) and tend to segregate to the islet 
core, with other cell types arranged closer to the mantle. 
1.1.2 Beta cell Biology 
The islets of Langerhans, discovered by a medical student 121 years ago, occupy a pivotal 
position in the endocrine control of fuel metabolism. The islets of Langerhans, taken together, 
can be thought of as a single organ occupying - 1% of the pancreas. Islets have a central core 
of insulin-containing β-cells and a surrounding mantle of glucagon-containing α-cells, 
somatostatin containing δ-cells, and pancreatic polypeptide-containing PP cells (4). The 
largest portion of the pancreas, the dorsal lobe, is derived from the embryonic dorsal anlage, 
but a smaller portion, the ventral lobe making up the inferior aspect of the head, is derived 
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from the ventral anlage. The islets of the dorsal lobe have mantles, which contain mostly α- 
cells and δ-cells, whereas the islets of the ventral lobe have mantles that consist mostly of PP 
and δ-cells. Islets are innervated by sympathetic nerves, parasympathetic nerves, and the 
poorly understood peptidergic nerves (5). 
 Islets are richly vascularized by direct arteriolar blood flow. Studies with microspheres have 
shown that islets, which make up only 1% of the mass of the pancreas, receive at least 10 % 
of the blood flow (6). Small arterioles enter the β-cell-containing core of the islet through 
discontinuities or pores of the mantle, and then break into a glomerular-like network of 
fenestrated capillaries which coalesce into collecting venules either during or after leaving the 
islet (7).  
Fig 1-1 Anatomy of Pancreas a. Gross anatomy of the pancreas; b. The exocrine pancreas; c. 
A single acinus; d. A pancreatic islet embedded in exocrine tissue. 
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The microvasculature of the core has a unique relationship with β-cells, which are now 
known to be polarized- with one domain facing an arterial capillary and another facing a 
venous capillary (8). The β-cells resembles other epithelial cells, having a basolateral portion 
and an apical portion; the latter contains relatively more insulin secretory granules. In 
addition, there are canaliculi, which are located between the lateral surfaces of β-cells, and 
span the distance from the arterial to the venous domains. These canaliculi contain large 
numbers of microvilli, which have been found to be enriched in the recently described β-cell 
glucose transporter (9). The presence of these elaborate structures suggests that interstitial 
fluid flows through these canaliculi in an arterial to venous direction and that glucose uptake 
of β-cells is carried out primarily by the transporters on these microvilli. Thus, these 
canaliculi may serve as the initial interface for glucose sensing by the β-cells. Through these 
glucose transporters extracellular glucose rapidly equilibrates with cytosolic glucose and is 
phosphorylated, with glucokinase serving a key rate-limiting function; glucose metabolism is 
tightly linked to the rate of insulin secretion (10). 
1.2 Pancreas Regeneration 
Regeneration of the endocrine pancreas has been studied in different experimental models that 
differ in the extent and selectivity of the tissue injury that is inflicted. The two major types of 
injury are caused by toxic drugs and surgery, respectively (11).  
1.2.1 Toxic Injury 
Selective destruction of beta cells can be obtained by injecting streptozotocin or alloxan. 
Streptozotocin is a DNA-alkylating agent and alloxan a generator of oxygen free radicals, 
both causing extensive DNA damage (12) . The capacity to regenerate following a toxic insult 
like streptozotocin rapidly declines during the first 5 days of life in rats (13). This indicates 
that beta-cell regeneration beyond the critical perinatal time window is inefficient, possibly 
because there is no more neogenesis operating from precursor cells. Interestingly, when the 
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hormone Glp-1 is administered to streptozotocin-treated newborn rats, beta-cell neogenesis is 
stimulated, and this results in improved glucose homeostasis persisting at adult age (14). In a 
recently described experimental model of β-cell destruction by alloxan, the combination of 
two factors, gastrin and EGF, were found to restore glycemic control in mice (15). In this 
model of beta-cell regeneration, a beta-cell growth rate of 30% per day was observed, leading 
to a beta-cell population doubling time of only 3 days. Although there was no complete 
regeneration of the original β-cell number after subtotal destruction, regenerative growth 
induced by the gastrin and EGF treatment led to the restoration of 30–40% of the normal beta-
cell mass within 7 days. The treatment had no effect on beta-cell replication, cell size, or 
apoptosis, and therefore, the regenerative effect could be attributed to neogenesis from 
precursor cells. Indeed, a pulse chase labeling with the thymidine analog bromo de-oxyuridine 
confirmed an influx of labeled cells from a replicating insulin-negative pool into the 
regenerating islets. The proliferating precursor cells express ductal-type cytokeratin markers 
(15). In NOD mice, beta cells are destroyed by a spontaneous autoimmune reaction leading to 
a type 1-like diabetes condition. Immune suppression in combination with Glp-1 (analog) 
treatment could restore normoglycemia and improve islet histology (16). 
1.2.2 Surgical Injury 
Partial pancreatectomy represents another model of tissue injury wherein regeneration has 
been studied in rodents. Surgical removal of part of the pancreas is followed only by a limited 
regenerative growth, and there is never a complete restoration of the original pancreatic 
volume. Furthermore, the regenerative response is proportional to the amount of pancreas 
removed. If half the pancreatic volume is left after hemipancreatectomy, this residual 
pancreas will grow only 20%. In the case of one-third of the volume being left after two-
thirds pancreatectomy, the residual pancreas grows only 30%. When only one-tenth of the 
volume is left after subtotal pancreatectomy, the residual pancreatic volume grows 80% (17). 
Glp-1 receptor knockout mice showed worse glucose intolerance after partial pancreatectomy 
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compared with wild-type mice, and this correlated with a significant defect in β-cell mass 
regeneration (18). An experimental model that leads to robust hyperplasia of β-cells is partial 
duct ligation. This consists in the closure, or ligation, with surgical thread of part of the main 
duct of the pancreas. As a consequence of this obstruction, exocrine secretory products will 
leak into the interstitial space and lead to tissue damage and inflammation. The part of the 
pancreas that lies downstream of the ligation (~50% of the pancreatic volume) is not affected 
histologically and continues to function normally. During the first week post ligation, a 
pronounced β-cell hyperplasia occurs in the ligated part, although the animals remain 
normoglycemic. β-cell replication is only slightly elevated, which is strongly suggesting that 
the increased β-cell number results from self-renewal by the β-cells. This is also indirectly 
indicated by the observation of intermediate phenotypes between ductal and endocrine cells 
(19). 
1.3 Incretin Hormones 
Incretin hormones are released from enteroendocrine cells from the gut and are secreted into 
the blood stream when food containing glucose, fat or protein hydrolysate enters the 
duodenum. Glucose-dependent insulinotropic peptide (GIP, also referred to as gastric 
inhibitory polypeptide) and glucagon-like peptide 1 (GLP-1) are the main incretin hormones 
(20; 21). GLP-1 is produced in the L-cells, which are located in high concentration in the 
distal intestine, whereas GIP arises in the K-cells, which are found predominantly in the more 
proximal intestine (22). 
1.3.1 Glucagon Like Peptide-1 (GLP-1) 
The 30-amino acid peptide hormone, glucagon-like peptide 1, is a product of the glucagon 
gene. This gene is expressed, not only in the A cells of the pancreas, but also in the endocrine 
L cells of the gut mucosa (23; 24). The L cells are at least as numerous as are A cells in the 
pancreas. However, the outcome of glucagon gene expression in the gut differs completely 
   
 6 
from that of the pancreas. The primary translation product, proglucagon, a peptide of 160 
amino acids, contains, apart from the glucagon sequence, two glucagon-like sequences 
designated GLP-1 and GLP-2. They are glucagon-like because, with respect to amino acid 
sequence, they are about 50% homologous to glucagon. When the prohormone is processed in 
the pancreas, the glucagon sequence is cleaved out, whereas the part containing the GLP is 
secreted as a single, large peptide (25; 26). In the gut, the glucagon sequence remains in a 
larger, presumably inactive, peptide designated glicentin, while the two glucagon-like 
peptides are cleaved out and secreted separately, in parallel with glicentin (25). Glicentin and 
the two glucagon like peptides are secreted in parallel, so results from investigations of 
enteroglucagon secretion might still, to some extent, be applicable to GLP physiology. 
Glicentin might be processed further, leading to the formation of an inactive N-terminal 
fragment and oxyntomodulin, the latter of which consists of the entire glucagon sequence and 
the C-terminal extension also found in glicentin. This molecule possesses some of the 
biological actions of glucagon (27), but is generally less potent and usually present in 
concentrations that are lower than those required for biological effects (28). 
GLP-1 is normally secreted in response to meal ingestion (29), with lipids and carbohydrates 
most active in stimulating secretion (30). The L cell is an open type endocrine cell with apical 
microvilli reaching the gut lumen, suggesting that the luminal concentration of lipids and 
carbohydrates might regulate L cell secretion directly. Meal responses occur rapidly (between 
5 and 30 min) after initiation of the meal, seemingly in contradiction to the predominantly 
distal location of the L cells within the gut. This has led to speculations that neural or 
endocrine mechanisms could play a role in initiating GLP-1 secretion. However, in support of 
a major role for luminal factors with respect to the meal response, luminal perfusions with 
lipids or carbohydrates have been demonstrated to elicit GLP-1 secretion (30). In addition, the 
meal response strongly correlated with the gastric emptying rate (31), indicating that it is the 
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rate of exposure of the gut mucosa to nutrients that determines the magnitude of the GLP-1 
response (32). 
1.3.2 Actions of GLP-1 
GLP-1 is a potent direct stimulator of insulin and somatostatin secretion from β- and δ-cells, 
respectively, and suppresses glucagon secretion from α-cells, either directly or indirectly, by 
the paracrine suppressive actions of insulin (33). The actions of GLP-1 to stimulate insulin 
secretion from β-cells are directly dependent on the glucose concentrations. The effectiveness 
of GLP-1 as an insulin secretagogue increases as the glucose levels rise and is attenuated as 
glucose levels fall (34) . This important property of GLP-1, and the other incretins such as 
GIP, to auto regulate the potencies of their actions on augmenting insulin secretion in step 
with ambient glucose concentrations provides a means to protect against hypoglycemia. A 
cellular mechanism in β -cells to explain this interdependence between glucose and GLP-1 
actions is described below and involves a synergetic cross-talk between the glycolysis 
(glucose metabolism) and cyclic adenosine monophosphate (cAMP) signaling pathways. This 
mutual interdependence between glucose metabolism and GLP-1 actions on β-cells is referred 
to as the glucose competence concept, that is, glucose is required for β -cells to respond to 
GLP-1, and GLP-1 (or other incretins) is required to render β-cells competent to respond to 
glucose (35). In addition to stimulating glucose-dependent insulin secretion, GLP-1 stimulates 
transcription of the insulin gene, proinsulin mRNA levels, insulin biosynthesis, and 
accumulation of cellular stores of insulin (36). GLP-1 stimulates the formation of cAMP and 
the cAMP signaling pathway stimulates transcription of the insulin gene by activating the 
DNA-binding transcription factor CREB (37), which binds to a key cAMP response element 
(CRE) located in the promoter of the insulin gene and thereby enhances the efficiency of 
transcription of the gene. The intracellular signaling cascade that mediates cAMP-induced 
effects on insulin gene transcription remains unclearly defined (38). Nuclear activity in 
response to GLP-1–mediated increases in cAMP includes recruitment of the CREB-binding 
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protein (CBP) that couples the protein–DNA complex. This complex consists of CREB bound 
to the CRE and CBP bound to CREB, resulting in enhancement of insulin gene transcription. 
Discrete from its effects on insulin gene expression via cAMP/CREB, GLP-1 also stimulates 
the recruitment of PDX-1 from the cytosol to the nucleus, leading to enhanced DNA binding 
and transcriptional activity of the insulin gene. Whereas translocation of PDX-1 was shown to 
be dependent on cAMP/protein kinase A (PKA) (39), the PDX-1 DNA binding activity was 
determined to be phosphatidylinositol (PI) 3-kinase dependent (40). 
   
Fig1.2. Functional responses to glucagon-like peptide-1 (GLP-1) receptor signaling in β-cells. 
 
1.3.3 GLP-1 and β cell proliferation 
GLP-1 increases the expression level of the β-cell-specific transcription factor pancreatic and 
duodenal homeobox gene-1 (PDX-1) (36), which is implicated in the regulation of the 
expression of insulin, GLUT2, and glucokinase genes and in β-cell differentiation (41-43). In 
addition, the glucoincretin increases in vitro β -cell proliferation nonadditively with glucose 
via a phosphatidylinositol (PI) 3-kinase/protein kinase C ζ signaling pathway in β (INS-1) 
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cells (40; 44), as well as the islet mass in mouse pancreas in vivo (45). Finally, GLP-1 induces 
several immediate early response genes and proto-oncogenes in INS cells that are implicated 
in cell growth/apoptosis control, such as c-fos, c-jun, junD, and nur77 (46; 47). GLP-1 (10 
nM) was shown to induce an increase in DNA synthesis as measured by tritiated thymidine 
incorporation in the INS832/13 insulinoma cell line and in rat pancreatic islets, following a 
24-hr incubation (40). Exendin-4, a long-acting GLP-I agonist, stimulates both the 
differentiation of β-cells from ductal progenitor cells (neogenesis) and proliferation of β-cells 
when administered to rats in a partial pancreatectomy rat model of type 2 diabetes (48). 
1.3.4 GLP-1 and β cell neogenesis 
The de novo formation of islet cells in the adult pancreas and in particular β cell neogenesis is 
a controversial process with evidence indicating that it can occur, especially in the rodent and 
some recent evidence from transgenic mice showing otherwise (49). Many adult in vivo 
models have been used to demonstrate the potential for the ductular network to give rise to 
new β cells, including interferon gamma (IFN-γ) over expression, plastic wrapping of the 
pancreatic duct (in order to induce mild pancreatitis) and administration of gastrin and EGF 
(50).The ductal origin of β-cells from the insitu progenitors during acute injury had recently 
been controversial as cell lineage tracing studies concluded that the pancreatic ductal 
epithelium does not contribute to β-cell growth during acute regeneration(51) 
1.3.5 Glucagon Like Peptide-1 Receptor 
GLP-1R is a specific 7-transmembrane receptor guanine nucleotide-binding protein (G-
protein) coupled receptor (GPCR). It was first cloned from rat pancreatic islets (52)  and later 
from a human pancreatic insulinoma (53; 54) and a gut tumor cell line (55).The rat and 
human GLP-1R exhibit a 95% amino acid homology and are 90% identical (52; 54), differing 
at 42 amino acid positions (56). The human GLP-1R gene is located on the long arm of 
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chromosome 6p21 (57). GLP- 1R is a 64-kDa protein (58).	  GLP-1R is a member of the class 
B family consisting of many classical hormone receptors (59). Within class B, the receptors 
for the peptide hormones form a subclass of the glucagon receptor family, which also include 
receptors for glucagon, GLP-2, GIP, growth hormone releasing hormone (GHRH), and 
secretin (60-62). 
1.3.6 GLP-1 inhibitor-Dipeptidyl Peptidase IV (DPP -IV) 
DPP IV, a 110 KD cell surface glycoprotein, is a widely distributed serine protease that 
cleaves two amino acids from small peptides containing alanine or proline in the second 
position of the N-terminus of the peptide (63) .This enzyme, also known as the T-cell antigen 
CD26, is found in many locations including intestinal and renal brush-border membranes, on 
hepatocytes and capillary endothelial cells and in a soluble form in plasma (64). Although its 
specificity suggests a role of the metabolism of many endogenous peptides, it seems as 
though DPP IV activity is especially critical for inactivation of GLP-1. The in vivo N-terminal 
truncation of both endogenous and exogenous GLP-1 was likely to have a physiological role 
in mediating the rapid degradation of native GLP-1 (65; 66). The peptide has an apparent 
plasma half-life of only 1–2 minutes, with a metabolic clearance rate of 5–10 L/min, 
exceeding the cardiac output by a factor of 2 to 3 (67). In patients with type 2 diabetes, studies 
suggest a correlation between glycemic control and plasma DPP IV activity, but this does not 
seem to be correlated to the amount of intact biologically active hormone in plasma (68). 
Targeted disruption of the CD26 gene had increased levels of intact endogenous GLP-1 
supporting the importance of DPP IV in GLP-1 metabolism (69).  DPP IV inhibition was able 
to completely prevent the N-terminal degradation of native GLP-1 in vivo and this was also 
associated with enhancement of its insulinotropic effects (70; 71). 
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1.3.7 Dipeptidyl Peptidase Inhibitor 
Dipeptidyl peptidase-IV inhibitors, that can block the DPP-IV enzyme, can increase the 
endogenous GLP-1 level and thus enhances the incretin action. DPP-IV inhibitors are novel 
oral glucose-lowering agents, which may be used as monotherapy or in combination with 
other antidiabetic compounds, metformin, thiazolidinediones or even sulfonylureas. 
Sitagliptin, vildagliptin and saxagliptin are already on the market, either as single agents or in 
fixed-dose combined formulations with metformin. Other compounds, such as alogliptin and 
linagliptin, are in a late phase of development (72). The proliferative and anti-apoptotic 
actions of GLP-1 on islet β -cells have been mirrored by studies using DPP-IV inhibitors in 
diabetic rodents. High-fat–fed mice treated with low-dose streptozotocin followed by 2–3 
months of treatment with des-fluoro-sitagliptin showed improvement in fasting and 
postprandial hyperglycemia, increased pancreatic insulin content, and increased numbers of 
insulin-positive β-cells in association with normalization of β -cell mass and restoration 
toward normal of the β-cell: β-cell ratio (73). 
1.4 Diabetes mellitus 
Diabetes mellitus is a major health problem affecting more than 4% of the global population. 
There are two forms of the disease; type 1 diabetes results from autoimmune destruction of 
the β- cells of the islets of Langerhans and type 2 diabetes occurs as a result of a combination 
of reduced insulin sensitivity and impaired function of the insulin-secreting β-cells. The age 
of onset of type 2 diabetes is normally much later than for type 1, which occurs in childhood 
(74). 
1.4.1 Type 1 Diabetes 
Type 1 diabetes (Insulin dependent diabetes mellitus (IDDM) or Juvenile onset diabetes), is 
an autoimmune disease, where the islets are destroyed by immune system. The pathogenesis 
of the disease is attributed to both genetic and environmental trigger. In Europe the incidence 
of Type 1 diabetes is highest in the youngest age group. The rate of increase in incidence was 
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6.3%, 3.1% and 2.4% for children aged 0-5, 5-9 and10-14 years, respectively and the rapid 
increase in youngest age group is of concern for the policy makers (75).   
1.4.2 Type 2 Diabetes 
Type 2 diabetes is characterised by disorders of insulin resistance and insulin secretion. It is 
the most challenging health problems in the 21st century both in developed and developing 
countries, is among the leading causes of death and diabetic macro- and microvascular 
complications, resulting in increased disability and enormous health care costs. In the 
European Region, an average total diabetes prevalence of 7.8 % in the adult population (20 - 
79 years) or 48.4 million persons has been estimated in 2003 (76).  
1.4.3 Islet transplantation as a cure for Type 1 Diabetes 
The patients suffering from Type 1 diabetes require exogenous insulin for the normalization 
of blood glucose level but the normalization of metabolic control cannot be achieved. Recent 
clinical trials and experimental models suggest that islet transplantation would be of potential 
use for type 1 diabetes. Owing to the introduction of better technology for the separation of 
islets and recent advances in immunosuppressive strategies, islet transplantation results have 
markedly improved. But major challenges remain to be addressed for the lifelong use of 
immunosuppressive drugs, which limits the indication for islet transplantation (77).  
1.4.4 Islet transplantation and regeneration 
Regeneration of islets was made possible by auto transplanting islets from the 
pancreatectomised mice and rats. These islet grafts had an increased blood flow due to 
improved vascular engraftment, which also increased the capacity of insulin secretion and 
larger endocrine volume. This was attributed to the release of survival signals such as VEGF, 
GLP-1 and REG (78). Islet transplantation after 70% partial pancreatectomy enhanced the β-
cell mass and insulin content in the remnant pancreas resulting from increased β -cell 
proliferation/neogenesis and also due to prevention of β-cell apoptosis (79). 
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1.5 Islet vasculature 
Islets contains a glomerulus-like micro vessel arrangement that is specific to islets alone and 
not observed in other tissues (80). Pancreatic islets are highly vascularized by a dense 
network of capillaries and are approximately five times denser in islets than in the 
surrounding exocrine tissue. Islets receive 7-10% of the total pancreatic blood flow, although 
they account of 1% of the total pancreatic mass (78; 81). 
 
Fig 1-3. Three-dimensional architecture of an islet.	   Islets are richly irrigated by a well 
developed microvasculature and endocrine cells are in contact with extracellular matrix 
(presumably deposited, at least in part, by neighboring endothelial cells) as well as being 
selectively innervated. Adapted from Halban PA, 2004 (82) 
The blood flow mechanism in islets is an inner-outer pattern, whereby the capillaries perfuse 
β-cells before other islet cell types (83). β -cells are closely associated with islet endothelial 
cells and are no more than one cell distant from the blood stream (84). 
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Fig1-4. Micrograph showing the rich vascularity of a human pancreatic islet. The micro 
vascular endothelium is visualized by staining with the lectin Bandeiraea simplicifolia (red). 
Adapted from Olsson, R, 2006 (84) 
1.5.1 The Pancreatic islet endothelial cell 
The endothelial cells and hematopoietic cells seem to derive from the same precursor cell, the 
haemangioblast. The islet endothelium functions as both a cellular barrier as well as allows 
rapid passage of proteins such as the endocrine hormones into the blood stream (84). The islet 
endothelial fenestrae are sites through which proteins can quickly permeate, which crucially 
depends on the VEGF-A secretion from the neighbouring β-cells (85). Several of the most 
important vasoactive substances such as nitric oxide (NO), angiotensin II and endothelin are 
produced or processed by the islet endothelial cells themselves (86). Several studies indicate 
that islet endothelial cells produce a number of factors involved in the regulation of 
angiogenesis, including both potent proangiogenic factors such as VEGF and angiostatic 
factors such as endostatin, pigment epithelial-derived factor and α1-antitrypsin (87; 88). 
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Fig 1-5. Schematic picture outlining some major functions of the islet endothelial cell. RBC, 
red blood cell; NO, nitric oxide; HGF, hepatocyte growth factor; VEGF, vascular endothelial 
growth factor; PEDF, pigment endothelial derived growth factor; EC, endothelial cell; BM, 
basal membrane. Adapted from Olsson R, 2006 (84). 
1.5.2 Revascularization of Islet graft 
Islet isolation often severe the microvasculature and damages the endothelial cells. Therefore 
the transplanted islets must re-establish a functional vascular network, by a process believed 
to involve angiogenesis and vasculogenesis (89). Revascularization of transplanted islets 
should be rapid and adequate for its survival and function or else it will be deprived of oxygen 
and nutrients, resulting in the islet cell death and early graft failure (90). On the contrary these 
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transplanted islets are less vascularized immediately after transplantation, and even several 
weeks thereby maintaining hypoxic conditions than the native islets (91). Until recently 
endothelial cells from the transplant recipient were thought to be the major contributor of 
angiogenesis but recent finding by using lac Z or GFP- tagged donor endothelial cells, suggest 
that the donor endothelial cells also play an important role in islet vascularization (92-94). 
1.5.3 Proangiogenic factors in the revascularization of islet graft 
Although there are several proangiogenic factors involved in the revascularization of islet 
graft, factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor 
(FGF), Angiopoietin-2 and Platelet-derived growth factor-B(PDGF-B)  promote the 
vascularization of islet grafts (95; 96). VEGF is also expressed in the pancreatic islets, but its 
expression in transplanted islets is significantly reduced 2–3 days post transplantation (94). 
1.5.4 Angiogenesis of islet engraftment 
Vasculogenesis and angiogenesis are the two mechanisms for the formation of new blood 
vessels. Vasculogenesis is the formation of new blood vessels from angioblasts that occurs in 
embryo where as angiogenesis is the formation of new blood vessels from pre-existing blood 
vessels which occurs in adult. Angiogenesis is further divided into vascular sprouting and 
intussusception. Vascular sprouting is the elongation/outgrowth of a pre-existing vessel and 
intussusception is the formation of new blood vessels by the ingrowths’ of transcapillary 
tissue pillars into existing blood vessels, which increases the vascular density (97). Isolated 
pancreatic islets are avascular and they depend on the neo-vasculation of microvasculature to 
re-establish nutritional blood supply. This condition leads to prolonged hypoxia as long as the 
islets are dependent on the diffusion of oxygen and nutrients from surrounding tissues. In the 
islet transplantation model, the islets are exposed to hypoxia immediately after transplantation 
in the portal as well as under the kidney capsule (98; 99).  
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1.5.5 The HIF-1α system 
The HIF system is activated in hypoxic cells to induce angiogenesis. HIF-1 is an αβ 
heterodimeric transcription factor of which the HIF-1β subunit is constitutively produced 
whereas the HIF-1α subunit is produced upon induction by hypoxia. The HIF-1α is 
hydroxylated and thus the transcription activity is inhibited, meaning that the HIF-1 
heterodimer is formed during hypoxic conditions. But the cellular threshold for the activation 
of HIF-1 system seems to differ between tissues. Following the formation of HIF-1αβ 
heterodimer, it interacts with the hypoxic response elements to induce the transcription of pro-
angiogenic factors such as VEGF, VEGFR2 and NOS. Furthermore, it also induces the 
expression of several pro and anti-angiogenic factors (100). Angiogenesis is induced when 
tissue produces more pro-angiogenic factors than anti-angiogenic factors (97).  
1.5.6 HIF-1α independent regulation of VEGF and Angiogenesis 
PGC-1 is a nuclear protein of 90 kDa containing SR domains and an RNA-binding motif 
characteristic of certain splicing factors (101). PGC-1α is a powerful modulator of oxidative 
metabolism whereby it regulates the oxidative metabolism, mitochondrial biogenesis and 
respiration.	   PGC-1α along with the ERR-α, is a mediator of signalling in response to 
deprivation of nutrients and oxygen, and that it powerfully regulates VEGF and other 
angiogenic factors to elicit neovascularization in vivo (102). 
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Fig 1-6. Model for the role of PGC-1  in the regulation of angiogenesis during exercise and in 
response to ischemia. Adapted from Arany Z, 2008 (102). 
1.5.7 Role of CREB in angiogenesis 
CREB is a cellular transcription factor and plays an important role in endothelial cell function 
and angiogenesis by mediating cellular responses to VEGF(103) 
1.4.5.8 Role of mTOR and P70S6Kinase in vasculogenesis 
Activated mTOR regulates the rate of protein synthesis for select mRNAs by activating the 
translational proteins S6Kinase and 4E-binding protein 1. It also regulates the cell growth and 
angiogenesis(104) and induces VEGF, platelet-derived growth factor-β  and transforming 
growth factor-α(105).  
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2. Aim of the study 
The general aim of this thesis is to study the role of Dipeptidyl peptidase inhibition on β-cell 
regeneration and revascularization in pancreatectomy and islet transplantation. In particular, 
we sought to study the role of endogenous incretin hormone, GLP-1 on β -cell proliferation 
and revascularization during pancreratectomy and islet transplantation under kidney capsule. 
Thus the specific aim of this thesis includes. 
 1. To evaluate the role of DPP-IV inhibition on β-cell proliferation. 
2. To study the revascularization potential of the islet graft upon DPP-IV inhibition. 
3. To study the pathway involved in the role of regeneration and revascularization. 
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3.Materials and Methods 
3.1 Materials 
3.1.1 Chemicals 
Chemicals        Company 
3,3’-diaminobenzidine tetra Hcl     Sigma 
Avertine         Sigma 
Biotinylated Bandereira Simplicifolia    Sigma 
Bovine Fibrinogen       Sigma 
Bovine Serum Albumin (BSA)     Sigma 
Bromodeoxyuridine       Sigma 
Collagenase        Sigma 
Crystal Violet        Sigma 
Dithiothreitol (DTT)       Invitrogen 
DNAse I         Qiagen 
Donkey serum       Jackson ImmunoResearch 
Ethanol         Merck  
Ethylenediaminetetraacetic acid (EDTA)    Fluka 
Fetal Calf Serum (FCS)      Biowest 
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Ficoll         PAA 
Formaldehyde        Roth 
Fuchsin         Sigma 
Gentamycin        Invitrogen 
Glo-Reagent        Promega 
Glucose         Sigma 
Glutamine         Invitrogen 
Hank’s Buffered Salt Solution (HBSS)    Invitrogen  
Hepes Buffer        Sigma 
Hoechst 33342       Sigma 
Isoflurane         Baxter 
Isopropanol        Merck 
Kayser’s Glycerine Gelatine      Sigma 
Levamisole        Sigma 
MCDB131 Medium       Invitrogen 
Mouse Alkaline Phosphatase      DAKO 
Neuraminidase Type X      Sigma 
Oligo (dT)20        Invitrogen 
Paraformaldehyde       Merck 
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Penicillin/Streptomycin      Invitrogen 
Peroxidase Anti Mouse IgG2      DAKO 
Phosphate Buffered Saline (PBS)     B Braun 
Picric Acid        Sigma 
Prolong Gold        Invitrogen 
RNAse-Free Water       Invitrogen 
Sitagliptin         Merck 
Sodium Hydroxide       Merck 
StreptABComplex       DAKO 
Streptozotocin (STZ)       Sigma 
Sucrose         Merck 
SYBR Green        Invitrogen  
Thrombin         Invitrogen 
Tissue-Tek OCT Compound      Sakura 
Trasylol         Bayer 
Tris-Hcl         Sigma 
Trizol         Invitrogen  
Trypan Blue        Sigma 
 
   
 23 
 
3.1.2 Antibodies 
Primary Antibody     Dilution  Company 
Guinea Pig Anti-Insulin, PolyClonal   1:100 (IHC, IF) DAKO 
Mouse Anti-BrdU, Monoclonal   1:100 (IHC)  DAKO 
Rabbit CREB (48H2), Monoclonal   1:100 (IF)  Cell Signal 
Rabbit p70S6 Kinase (49D7), Monoclonal  1:100 (IF)  Cell Signal 
Rabbit pCREB (Ser133) (87G3), Monoclonal 1:100 (IF)  Cell Signal 
Rabbit pmTOR (Ser 2448)(D9C2), Monoclonal 1:100 (IF)  Cell Signal 
Rabbit VEGF (A-20), Polyclonal   1:100 (IF)  Santa Cruz 
Rabbit VEGF R2 (55B11), Monoclonal  1:100 (IF)  Cell Signal 
Rat Anti-Mouse CD11B, Monoclonal  1:100 (IF)  Immunotools 
 
Secondary Antibody     Dilution Company 
FITC-APure Donkey Anti Rat   1:500 (IF) Jackson ImmunoResearch 
FITC-APure Donkey Anti.Guinea Pig  1:500 (IF) Jackson ImmunoResearch 
Rhod Red-X-APure Donkey Anti-Guinea Pig 1:500 (IF) Jackson ImmunoResearch 
Rhod Red-X-APure Donkey Anti-Rabbit  1:500 (IF) Jackson ImmunoResearch 
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3.1.3 Kits 
Kits         Company 
BCA Protein Assay Kit      Thermo Scientifc Pierce 
Human Insulin ELISA Kit      DRG Instruments 
Mouse Insulin ELISA Kit      DRG Instruments 
Mouse VEGF Quantikine ELISA Kit    R&D Systems 
Porcine Insulin ELISA Kit      DRG Instruments 
RNeasy Micro Kit       Qiagen 
RNeasy Mini Kit       Qiagen 
SuperScript III Reverse Transcriptase    Invitrogen 
3.1.4 Human Primer sequences for realtime PCR 
Genes Forward Primer     Reverse Primer 
ARNT GCTGGGAGATCAGAGCAACAGCTACAA TGTTTCTTTCCAGAGGGACTG 
GAPDH TGATGACATCAAGAAGGTGG  TTTCTTACTCCTTGGAGGCC 
HIF-1α TTCACCTGAGCCTAATAGTCC  CAAGTCTAAATCTGTGTCCTG 
PGC-1α AGTACAACAATGAGCCTTCAA  CATCAAATGAGGGCAATC 
VEGF-A CCTCCGAAACCATGAACTTT           TTCTTTGGTCTGCATTCACATT 
VEGF-R2 CCAGTCAGAGACCACGTTT    AGTCTTTGCCATCCTGCTGA 
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3.1.5 Instruments 
Instrument      Company 
Cell Processor (COBE 2991)    COBE 
Cryostat Maschine (Leica CM1850)  Leica  
ELISA Plate Reader     Brethold Technologies-Mithra LB940 
Fluorescent Microscope    Leica Microsystems  
Gel Doc       Vilber Lourmat 
Hamilton Syringe     Hamilton 
Laser-Dopler Flow Cytometer   Perimed 
NanoDrop 1000 Spectrophotometer   Thermo Scientific 
OneTouch Ultra2 Glucometer   LifeScan  
StepOne Plus Real-Time PCR System  Applied Biosystems 
3.1.6 Softwares  
Softwares        Company 
Adobe Illustrator CS4     Adobe 
Adobe Photoshop CS4     Adobe  
EndNote   X4     Thomson Reuters 
GraphPad Prism 5.0     GraphPad Software  
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Image J 1.45      National Institutes of Health 
Leica Application Suite     Leica 
Motic Image Plus 2.0      Motic     
3.1.7 Animals 
 Male C57Bl/6 mice and inbred athymic NMRI nu/nu mice (12 weeks old) were 
purchased from Charles River (Sulzfeld, Germany). Animal research was approved by 
Regional Commission Giessen, Germany under the code number GI20/11-Nr.15/2006. 
Animal husbandry was performed according to the German Animal Welfare Law as published 
in the latest version under http://bundesrecht.juris.de/tierschg. 
3.2 Methods 
3.2.1 Experimental Design 
 Parital Pancreatectomy (60%) and Islet transplantation model was used  to study 
the effect of DPP-IV inhibition on β-cell regeneration. 
3.2.1.1 Partial Pancreatectomy 
   Partial Pancreatectomy (60%) was done in 12 weeks old male C57Bl/6 mouse. 
The animals were anaesthetized with avertine and maintained on isoflurane. Animals were 
shaved off the hair in the abdominal region. A midline insicion was made and the pancreas 
was identified as a pinkish organ along with the spleen by slowly pulling out the intestine 
with a moisturized guaze.Now the pancreas was exposed along with the spleen. The blood 
vessels were tied with an absosrbable suture  one  in the region of spleen and the other at the 
head region of the pancreas where it joins with the duodenum. Now the spleenic porton of the 
pancreas was removed with a pair of scissors leaving behind the hepatic or intestinal region of 
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the pancreas. Now the abdomen was sutured with an absorbable suture and the skin was 
clamped with surgical staples. Sham operation was also done for control animals by 
performing the surgery without removing the pancreas 
3.2.1.2  Experimental Groups: 
 The partially pancreatectomised and sham operated mice were randomly assigned 
into two different groups. 
Px+NC - Partial Pancreatectomy (60%)  and Normal chow fed animals 
Px+SG - Partial pancreatecttomy (60%) and 5.5 % sitagliptin mixed diet. 
The animals were kept at ad libidum feed and water and maintained in  12:12 Light : Dark 
cycle until the intended period of time 
3.2.1.3 Blood Glucose measurement 
  Blood glucose was measured using  One Touch®  Ultra®2 (LifeScan) on every 
alternate days from the tail vein. 
3.2.1.4 Bromo-de-oxyuridine (BrdU) injection 
Bromodesoxyuridine (BrdU; 100 mg/kg body weight) was injected intravenously for 
three days to study the endogenous β-cell proliferation. 
3.2.1.5 Intraperitoneal Glucose Tolerance Test (IPGTT) 
 Intraperitoneal Glucose Tolerance Test was performed at the end of the experiment. 
After measuring the blood glucose  at  0 min, glucose solution (20%) was immediately 
injected intraperitoneally to each mouse and the thereafter the blood glucose was measured at 
30, 60,90 and 120 minutes post glucose injection.  
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3.2.1.6 Pancreatic Insulin content measuremnet 
 After the intended days of treatment the remaining pancreas was removed from 5 
animals in each group and the pancreas was homogenised with IRI buffer and the insulin 
extracted with acid-ethanol method overnight. 
3.2.1.7 Insulin ELISA 
Insulin content of the  pancreas was estimated using a mouse Insulin ELISA kit (DRG, 
Germany).For the measurement of the insulin content the manufacture’s protocol was 
followed. 
3.2.1.8 Immunohistochemistry-Light Microscopy 
 After the intended days of  treatment the remaining pancreas was removed from 5 
animals from each group and fixed with zamboni’s fixative.After 30 minutes of fixation, the 
pancreas was washed 3x with PBS and kept in PBS solution overnight at 4°C.The next day it 
is kept in sucrose solution overnight at 4°C.Then it is embedded in a cryoblock using OCT 
medium and frozen.The cryosections were made and stained for Guinea Pig Anti-Insulin 
(Polyclonal,Dako) and anti-BrdU antibodies to measure the area of islet and the rate of 
proliferation. 
3.2.2 Islet transplantation 
The experimental design was investigated in three islet transplantation models with mice as 
recipients.  
3.2.2.1 Mouse islet transplantation  
Sitagliptin (5.5% w/w) was administered to mice together with their chow due to short 
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duration of action in rodents (Altromin, Lage, Germany) while control mice received standard 
lab chow without sitagliptin. Blood glucose was monitored regularly with a handheld 
glucometer. We used a murine model of minimal islet mass transplantation. A suboptimal 
number of islets isolated from syngenic donor mice (50-70 per graft) were transplanted under 
the capsule of the upper pole of the kidney in C57Bl6 mice made diabetic with streptozotocin 
(180 mg/kg). Diabetes was defined as non-fasting blood glucose >350 mg/dl measured at two 
successive days.  Mice were anaesthetized with 2.5% avertine (200 µL/100 g, Sigma), and the 
kidney was accessed by an incision on the left flank. A small nick was made in the kidney 
capsule with the bevel of a 20-gauge needle over the inferior renal pole. The sterile 
polyethylene tubing containing islets was then connected to a 0.5 mL Hamilton syringe and 
advanced under the capsule through the nick toward the superior pole of the kidney where the 
islets were deposited. The wound was closed in two layers with absorbable sutures. Three 
days after explantation of the graft, the blood glucose levels were analysed again to verify the 
recurrence of diabetes. Kidneys containing islet grafts were removed from the recipient 
mouse for further processing after 10 weeks. 
3.2.2.2 Human islet transplantation  
In the second model of islet transplantation 2,000 islet equivalents of human islets were 
transplanted beneath the kidney capsule of diabetic nu/nu NMRI mice. Human pancreatic 
islets were obtained from a single multiorgan donor utilizing a continuous digestion-filtration 
device modified as described before (106). After 10 weeks of treatment with sitagliptin the 
human islet grafts were retrieved for insulin extraction. At the end of the experiment 
bromodesoxyuridine (BrdU @ 100mg/kg body weight) was injected i.v. for three days to 
study β-cell proliferation in islet grafts.  
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3.2.2.3 Porcine islet transplantation 
Porcine islets were isolated using previously described techniques of collagenase digestion 
and Ficoll purification (107; 108) at the Islet Isolation Facility of Third Medical Department, 
Uni-Giessen. About 2,000 islet equivalents of porcine islets were transplanted beneath the 
kidney capsule of diabetic nu/nu NMRI mice. 
3.2.3 Insulin content of islet grafts  
For insulin measurement, the transplants were homogenized mechanically and dissolved in 
acid ethanol, as described before (109). The supernatant was collected for species-specific 
insulin ELISA after centrifugation at 3,000 rpm for 10 minutes (DRG Instruments GmbH, 
Marburg, Germany).  
3.2.4 Islet area measurement 
Kidneys were retrieved 10 weeks after human islet transplantation, snap-frozen in O.C.T. 
medium, serial sections were made at 7µm thick. Every 20th section was stained for insulin to 
identify the β-cells. The sections were fixed in Zamboni’s fixative for 10 minutes and washed 
thrice for 5 minutes. After blocking in PBS containing 1% BSA and 2% donkey serum, the 
cryosections were probed with antibodies insulin (Polyclonal Guinea pig anti-insulin (1:200), 
Cat.No:A0564, Dako, Germany) and Monoclonal Antibody M1/70.15 to CD11b (Mouse) 
(1:200,Cat-No:22159111, Immunotools, Germany) at 4°C overnight. Secondary Rhodamine 
Red-coupled anti-guinea pig and FITC-coupled anti-mouse (1:500, Jackson ImmunoResearch, 
USA) antibodies were applied on the next day. The cover slips were mounted with Prolong 
Gold (Invitrogen), visualized and photographed using a Leica DMLB microscope (Leica, 
Germany) equipped with Leica DFC420C CCD and processed in Leica Application Suite. 
Insulin immunostained sections were scanned using Motic image analysis software 2.0 system 
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and analyzed. Total β-cell area was determined in 5-10 sections from the control and the 
sitagliptin-fed group. 
3.2.5 Proliferation of β-cells 
Staining for bromo de-oxyuridine (BrdU) incorporation was performed as described before 
(109). Briefly, sections were incubated with a mixture of nuclease and mouse alkaline 
phosphatase-conjugated anti-BrdU monoclonal antibody (dilution 1:200,Cat. no. 1758756, 
Boehringer Mannheim) for 1 h at room temperature, washed for 15 min with Tris-HCl, and 
incubated with a peroxidase antimouse IgG2 for 30 min and stained with 3,3’-
diaminobenzidine tetra hydrochloride using peroxidase. After BrdU labelling the sections 
were washed and then stained for insulin with guinea pig anti-insulin polyclonal antibody 
(dilution 1:200, incubation for 1 h at room temperature) and anti-guinea pig alkaline 
phosphatase secondary antibody (Dako). To calculate the proliferation rate of β - cells, cells 
stained for both insulin and BrdU were counted using light microscopy. The number of total 
β-cells inspected for proliferation in a single graft was 1000-1200. Results were expressed as 
the percentage of BrdU positive β-cells. 
3.2.6 Blood flow and microvascular Density 
The blood perfusion of the islet graft and the adjacent renal cortex was measured by laser-
Doppler flow cytometry (PF 4001-2, Perimed, Stockholm, Sweden) with a needle probe (411 
mm tip; outside diameter, 0.45 mm; Perimed). The flow probe was positioned perpendicular 
to the immobilized tissue surface by the use of a micromanipulator, and care was taken not to 
cause any compression of the tissue. 
Microvessels in histologic sections were identified by staining with biotinylated Bandereira 
simplicifolia (BS-1, Cat.No: L 5391 Sigma) as previously described (110). Briefly, slides 
were pretreated with neuraminidase type X (Cat.No:N2133, Sigma) and incubated with 
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biotinylated BS-1 at 4°C overnight. After three washings with PBS, they were incubated with 
StreptABComplex (Dako) for 30 minutes at room temperature. Subsequently, fuchsin and 1 
mM levamisole was added. Vascular area cross sections within grafts were calculated from 
lectin-positive fields in each section with a light microscope (200x) combined with an image 
analysis system (Motic, Wetzlar, Germany). Vascular density was expressed as percentage of 
vascular area to total area examined. 
3.2.7 Mouse islet isolation and culture 
Pancreatic islets were isolated from C57Bl6 or RIP-VEGF mice, a transgenic mouse model 
with human vascular endothelial growth factor (VEGF) production in β -cells under the 
control of the rat insulin promoter (RIP), at the age of 9-12 weeks (109). Briefly, pancreata 
were distended by collagenase solution (2.5 mg/ml), incubated in a water bath for 12 min at 
37°C and shaken by hand for 3 min under visual inspection. After washing twice in ice cold 
HBSS and centrifugation (900rpm, 3min) the remaining pellet was resuspended in Parkers 
FCS medium (TCM199 medium supplemented with 5% FCS, HEPES buffer, 
penicillin/streptomycin and gentamycin). Pure islets were handpicked under a 
stereomicroscope, which were incubated overnight (37°C, humidified air) to recover from the 
isolation stress.  
3.2.8 Assessment of VEGF secretion and DPP-IV activity 
VEGF concentrations of cell culture supernatants were measured by ELISA (R&D Systems). 
DPP-4 activity in plasma samples or pancreatic islet was determined using the Glo-reagent for 
biological fluids (Promega). 
3.2.9 Ex vivo Islet Sprouting  
Bovine fibrinogen, supplemented with trasylol (prevents hyperfibrinolysis) was diluted in 
PBS Dulbecco’s to a final concentration of 1.7mg/ml. To the wells of a 24-well plate 300 µl 
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of this solution was added. After removing the exocrine tissue from the 24h pre-cultured islets 
and washing in PBS, around 20-30 islets were embedded into each of the prepared gels. All 
test substances were mixed into the liquid gels prior to polymerization with 5µl of thrombin 
(1000 U/ml). After clotting at room temperature gels were equilibrated with MCDB131 
medium (Invitrogen) containing 5% glutamine in an incubator with 5% CO2. The fibrin clots 
were soaked with 300µl Parkers FCS medium and cultured for 48h. After 48 h cultures, gels 
were fixed with 3% formaldehyde for 6 - 12 h and stained with crystal violet. Washed gels 
were transferred onto slides and fixed with Kayser’s glycerine gelatine. Islet vitality was 
scrutinized at two time points, firstly directly prior to the angiogenesis assay using the trypan 
blue staining and secondly by determination of islet morphology in the fixed gels. Vital islets 
did not disperse and had smooth shape without cellular protrusions. Photos were taken and 
sprout length was determined using Motic software (Wetzlar, Germany). Following the 
isolation procedure every individual experiment was carried out with an appropriate control 
condition.  
3.2.10 Quantitative Realtime PCR in human islet transplant 
3.2.10.1 RNA isolation 
Human islet transplants were carefully dissected from nu/nu NMRI kidney capsule one day or 
14 days following islet transplantation. Total RNA was immediately extracted with TRI 
reagent (Invitrogen) and the RNA pellet obtained after isopropanol and ethanol precipitation 
was dried and resuspended in 50 µl of RNase-free water. To prevent contamination of RNA 
by RNAses all standard precaution was taken. 
3.2.10.2 Measurement of RNA Concentration 
RNA concentration was measured using NanoDrop 1000 Spectrophotometer (NanoDrop, 
Wilmington). The ratio of sample absorbance at 260 and 280 nm (260/280) was measured and 
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it should be approximately 2.0 for pure RNA. Sample concentration was given in ng/µl based 
on its absorbance at 260 nm. 
3.2.10.3 DNAse Treatment 
 All RNA samples were treated with DNAse to eliminate any genomic DNA contamination. 
The following reagents were mixed in a microfuge tube and incubated at 37ºC for 15 min. To 
inactivate DNAse I, 1 µl of 25mM EDTA was added and incubated at 65oC for 15 min. The 
reaction was collected by a brief centrifuge and stored at -80 oC until used for reverse 
transcription. 
        RNA                               1 µg 
10X Reaction Buffer               1 µl 
       DNase I (1 U/µl)                     1 µl 
       RNAse/DNAse free water              upto 10 µl 
 
 3.2.10.4 cDNA synthesis 
 The sample containing 11 µl of the DNAse treated RNA was used for cDNA synthesis.The 
RNA was reverse transcribed into cDNA using  reverse transcriptase and Oligo(dT) 
primers.The RNA sample was mixed with 10mM 10 mM dNTPs (final concentration), 0.5µ g 
Oligo(dT)20 and H2O to 7µl. This mixture was heated at 65°C for 5 min, and quickly chilled 
on ice. Then, 4 µl of 5 x firststrand buffer and 2 µl of 0.1 M DTT were added to the sample 
and incubated at 42°C for 2 min.Finally, 1 µl of SuperScript II RT (200 U) was added to the 
mixture (total volume 25µl), followed by incubating at 42°C for 50 min and heating at 70°C 
for 15 min. A sample of 1µg total RNA was used for cDNA synthesis from Oligo (dT) 20 
primers using the Superscript TM II first strand synthesis system (Invitrogen).  
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3.2.10.5 Real -Time PCR analysis 
 Real time PCR or qPCR is used to detect the amplification of a specific target sequence from 
cDNA using gene-specific primers. 
The reaction mixture consists of the following reagents. 
SYBR Green Master Mix (2x)    5µl 
cDNA template     0.5µl 
Primers (F+R) 20pmol/µl    0.5 µl 
RNAse/DNAse free H2O    upto 10µl 
Real time- PCR was carried out  StepOne Plus real-time PCR cycler (Applied Biosystems) 
using the following programs: 
Steps Temp. Time Number of Cycles 
Enzyme activation 95°C 15 min 1 cycle 
Denaturation 95°C 15 sec  
40 cycles Annealing 60°C 30 sec 
Extention 72°C 30 sec 
 
After amplification of the products a melting curve analysis was performed to analyze the 
specificity of the products using the following steps. 
Steps Temp Time No.of Cycles 
Denaturation 95°C 30 sec 1 cycle 
Starting Temp. 60°C 30 sec 1 cycle 
Melting step 60°C 10 sec 80 cycles 
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The threshold value ct for each individual PCR product was calculated by the instruments’ 
software and CT values obtained for the target gene were normalized by subtracting the CT 
values obtained with the reference gene GAPDH. All data are presented as the ratio of the 
target gene/GAPDH. The relative abundance of the different genes was calculated by the 
comparative ΔΔCT method (111).  
3.2.11 Immunohistochemistry-Fluorescent Microscopy 
3.2.2.11.1 Measurement of VEGF, VEGFR-2, CREB, pCREB, pMTOR and P70S6K 
expression 
Sections were made from the retrieved graft and fixed with Zamboni’s fixative for 10 min and 
washed thrice for 5 min in PBS. After blocking in PBS containing 1% BSA and 2% donkey 
serum, the cryosections were probed with antibodies against insulin (polyclonal guinea pig 
anti-insulin antibody, Dako, Germany), Rabbit Polyclonal VEGF (Santa Cruz), VEGFR2, 
CREB and pCREB (Cell signaling) and Rabbit monoclonal pMTOR and P70S6K antibody 
(Cell signaling). Primary antibodies were visualized with FITC- coupled anti-Guinea pig and 
rhodamine-coupled anti-rabbit antibodies (Jackson Immuno Research, USA). Sections were 
mounted with Prolong Gold (Invitrogen), visualized and photographed using Leica DMLB 
microscope (Leica, Germany). The images were analyzed using Image J software for VEGF 
and VEGFR-2 area and for number of CREB and pCREB positive β-cell nuclei. 
3.2.12 Statistical analysis  
Statistical analysis was performed by Prism 5.0 (GraphPad Software, San Diego California, 
USA) using one-way analysis of variance and Bonferroni post-hoc tests. For two-group tests 
the student t-test was applied. Data from the transplantation experiment were plotted as 
survival curves with ‘cure of diabetes’ as non-recurrent event and analyzed by the Mantel-
Haenszel log rank test. 
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4. Results  
4.1 Sitagliptin increases proliferation of β-cells after pancreatectomy 
In this study we used pancreatectomy model and fed the mice with sitagliptin to assess the 
impact of pancreatectomy and sitagliptin on β-cell proliferation. We found that sitagliptin 
treatment increased the number of BrdU positive cells, indicating the proliferation potential of 
β-cells after pancreatectomy and sitagliptin treatment. The number of BrdU positive cells 
increased significantly (p<0.05) in the sitagliptin treatment compared to the control group 
(Figure 1 A, B and C). 
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Figure 4-1. β-cell proliferation after pancreatectomy and sitagliptin treatment. (A-Control, 
B-Sitagliptin). Light microscopic picture showing the proliferation of β-cell as measured by 
BrdU staining. (C). Quantitative measurement of β-cell proliferation. 
4.2 Sitagliptin increases Insulin area after pancreatectomy 
Next we assessed the insulin area after pancreatectomy and sitagliptin treatment and found 
that the insulin area was significantly (p<0.05) increased in the sitagliptin treated than the 
control group (Figure 2) 
 
Figure 4- 2. Quantitative Insulin area after pancreatectomy and sitagliptin treatment 
4.3 Sitagliptin improves glucose tolerance in pancreatectomized mice 
Intraperitoneal glucose tolerance test was performed in both control and sitagliptin group after 
pancreatectomy and found that sitagliptin treatment improved the glucose tolerance 
significantly (p<0.05) than the control group (Figure 3) 
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Figure 4-3: Intraperitoneal glucose tolerance test.  
4.4 DPPIV concentration and activity reduced by sitagliptin in both plasma and pancreas 
Since the sitagliptin treatment increased both the proliferation and insulin area of β-cells, we 
determined whether this might be due to actual inhibition of DPP-IV by sitagliptin and found 
that sitagliptin treatment significantly  (p<0.05) decreased both the concentration and activity 
in pancreas and plasma (Figure4A, B, C and D). 
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Figure 4-4. DPPIV concentration and activity in pancreas and plasma. (A, C). DPPIV 
concentration and activity was measured using Glo-reagent in pancreas. (B, D). DPPIV 
concentration and activity in plasma. PX+SG- pancreatectomy and sitagliptin; PX+NC- 
Pancreatectomy and Normal Chow. 
4.5 Sitagliptin accelerates restoration of normal blood glucose levels 
To determine the effect of sitagliptin on the cure of diabetes after pancreatic islet 
transplantation blood glucose levels were measured over a period of ten weeks. Cure of 
diabetes was defined as sustained reduction of blood glucose < 200 mg/dl. 
Diabetic C57Bl6 mice were hyperglycemic with a mean blood glucose level of 
350 ± 80 mg/dl. In previous studies it was shown that progression of severity of diabetes 
induced by streptozotocin (STZ) in rats was reduced by DPP-IV inhibitor(112). Subsequent 
to transplantation with a suboptimal number of pancreatic islets blood glucose levels 
gradually decreased. Three and ten weeks following transplantation 46% and 92% of the 
control group had returned to non-fasting blood glucose concentrations of less than 200 
mg/dl, respectively. In contrast, 100% of sitagliptin-treated mice reached non-fasting blood 
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glucose concentrations already after 3 weeks (Figure 5A, B). Thus, sitagliptin treatment had 
a beneficial effect on transplantation-mediated restoration of normal blood glucose levels in 
diabetic mice. 
 
Figure 4-5: Sitagliptin accelerates restoration of normal blood glucose levels. (A) C57Bl6 
mice were treated with a single dose of streptozotocin (180 mg/kg) and placed on either a 
normal chow diet o r  diet containing 5.5% sitagliptin following syngenic islet transplantation 
(day 0). Blood glucose levels (mg/dl) were determined in the control and sitagliptin treated 
mice. Tx = transplantation. Control = chow fed mice. Sitagliptin = Recipient mice fed with 
5.5% sitagliptin for 10 weeks. (B) Survival curves demonstrating cure from diabetes (< 200 
mg/dl) by transplantation up to 70 days after transplantation (p < 0.0072 vs. control). n=12. 
Data represent mean ± SEM. 
 
4.6 Improved insulin production through enhanced β -cell proliferation 
To determine the underlying cause of accelerated restoration of blood glucose levels 
we assessed the effect of sitagliptin on insulin production. Grafts and pancreases from 
recipient mice were retrieved and insulin content was determined. The mean insulin content 
of both mouse (Figure 6A) and human (Figure 6B) islet grafts was significantly higher in the 
sitagliptin-treated compared to the control group (mouse: 48 ± 10 vs. 35 ± 11 µg insulin/g 
kidney, p < 0.03; human: 106 ± 6 vs. 58 ± 6 µg insulin/g kidney, p < 0.01).  
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Figure 4 - 6: Sitagliptin improves insulin production. (A) Pancreatic insulin content 
of mouse islet grafts transplanted to the kidney capsule given as µg insulin per g kidney. 
Control = normal chow, Sitagliptin = 5.5 % sitagliptin included into the rodent chow (p < 
0.05; n=6). (B) Insulin content of transplanted human islets 10 weeks after transplantation 
of 2,000 islet equivalents each and feeding the recipient NMRI nu/nu mice either with 
normal chow or chow enriched with 5.5% sitagliptin (p < 0.01). Data represent mean ± 
SEM.   
  
These results were confirmed by immunocytochemistry of sections of transplants and 
pancreases utilizing insulin antibodies. Insulin-positive areas were markedly greater in graft 
sections of sitagliptin-treated mice (mouse: 1629 ± 126 µm2 vs. 1151 ± 145 µm2, p < 0.005; 
human: 3113 ± 690 µm2 vs. 1812 ± 10 µm2, p < 0.01) (Figure 7A and B). Staining with 
CD11b antibodies revealed no difference of immune cell infiltration (Figure 7C).  
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Figure 4-7:  Sitagliptin increases grafted insulin area. (A, B). Insulin area (µm2) of 
sections of mouse (A) and human (B) islet grafts transplanted to the kidney capsule. Insulin 
positive graft area for human islets was 3113 ± 690 µm2 in sitagliptin-treated mice and 
1812 ± 10 µm2 in control mice  (n=6, 10 sections per graft, p < 0.01). Data represent mean ± 
SEM.   (C) Effect of DDP-IV inhibition by 5.5% sitagliptin on insulin area and immune cell 
migration to human islets transplanted to kidney capsule of NMRI nu/nu mice. Grafted 
kidneys were recovered as described 10 weeks after transplantation. Representative cryo 
sections were stained for insulin (magenta) and CD11b  (green)-positive immune cells  
(neutrophils, macrophages). The white line  demarcates the graft and kindey cortex.  Area 
stained positive for insulin was larger in the sitagliptin group compared to control. No 
difference of immune cell infiltration was observed. 
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In sections of host pancreases insulin could not be detected indicating complete abrogation of 
endogenous insulin production by streptozotocin (data not shown). Larger amounts of insulin 
can be due to increased insulin biosynthesis per cell or greater number of actively producing 
β-cells or both.An earlier study reported that sitagliptin treatment in partially 
pancreatectomized mice increased β-cell mass in remnant pancreas(113). To determine 
changes in the biosynthesis of insulin we measured the expression level of PGC-1α and 
PDX-1 in islet grafts. Altered expression of these genes in pancreatic islets is accompanied 
by changes of cyclic AMP levels and glucose stimulated insulin secretion. [19][20] 
Interestingly, the expression of both genes was upregulated (Figure 8A, B).  
  
 
  
Figure 4-8: Sitagliptin promotes upregulation of PGC-1α  and PDX-1. (A,B ) Human 
islet grafts were retrieved from NMRI-nu/nu mice fed with either 5.5% sitagliptin or normal 
chow one day or fourteen days after transplantation (Tx). After RNA isolation and cDNA 
synthesis the relative expression of the indicated genes was quantified by real time PCR in 
triplicates. The effects of different stimulations on individual gene expression were calculated 
and normalized to endogenous reference gene GAPDH using comparative ΔΔCT method (* 
p < 0.05, ** p < 0.001). 
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This, however, could also be explained by an increased number of β -cells. Moreover, the 
areas of insulin positive tissue suggest an increased number of β-cells. This might be due to 
an enhanced proliferation rate or an antiapoptotic effect of sitagliptin. The anti-apoptotic gene 
Bcl-2 was increased by sitagliptin (Figure 9A). However, we did not detect a significant 
difference in the expression of the pro-apoptotic gene Bax (Figure 9B). Thus, we determined 
whether β -cell proliferation was affected by sitagliptin. Sitagliptin treatment significantly 
increased the number of BrdU-positive β-cells from 4.5 ± 0.5 per µm2 to 7.5 ± 2.6 per µm2 (p 
< 0.01; Figure 9C). These data suggest that the observed increased production of insulin after 
sitagliptin treatment is mainly due to enhanced β-cell proliferation. 
 
 
Figure 4-9:Sitagliptin increases anti-apoptotic gene Bcl-2 expression and promotes β-cell 
proliferation. (A). The anti-apoptotic gene Bcl-2 was increased by sitagliptin. (B). No 
difference in the expression of the pro-apoptotic gene Bax. (C). Quantitative analysis of β-
cells positive for bromodesoxyuridine (BrdU) in islet grafts transplanted to the kidney 
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capsule of mice on normal chow or chow containing 5.5% sitagliptin (p < 0.01; n=6; 10 
sections per graft). Data represent mean ± SEM. 
4.7 Sitagliptin improves vascularization 
Previously, it has been demonstrated that the capillary network of transplanted pancreatic 
islets has to be reconstituted(109) and vascularization of them occurred within 10-14 
days(114). To examine the effect of sitagliptin on re-vascularization islet transplants were 
retrieved after 10 weeks. Vascular density within the graft was calculated by morphometry 
after endothelial cell staining (Figure 10A). Sitagliptin treatment significantly increased the 
area occupied by endothelial cells from 53 ± 8 µm2 to 164 ± 15 µm2 (p < 0.001; Figure 10B) 
as well as the number of proliferating endothelial cells within and around the graft from 11 ± 
1 per µm2 to 31 ± 5 per µm2 (p < 0.002; Figure 10C). Collectively, these data suggest that 
DPP-IV inhibition by sitagliptin increases revascularization.  
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Figure 4-10: Sitagliptin enhances vascularization. (A) Representative picture of 
immunostaining of islet graft with lectin BS-1 (red) at the kidney capsule of control and 
sitagliptin-treated islet graft. Both graft area and lectin BS-1-positive areas are larger 
compared to control. The asterisk * marks the border between islet graft and kidney. (B) 
Quantitative analysis of area (µm2) stained positive for lectin BS-1 in islet grafts 
supplanted to the kidney capsule of C57Bl56 mice fed either with control chow or chow 
enriched with 5.5% sitagliptin (n=6; 10 sections per graft, p < 0.001). (C) Quantitative 
analysis of bromodesoxyuridine (BrdU)/lectin BS-1 double-positive cells in islet grafts 
transplanted to the kidney capsule of mice either on normal chow or chow containing 
5.5% sitagliptin (n=6; 10 sections per graft, p < 0.001). 
4.8 DPP-IV inhibition increases functional blood flow to transplanted islets 
To determine if re-vascularization also resulted in an improved blood flow we applied laser-
Doppler flowmetry. A needle probe was used to record signals up to 200 µm under the kidney 
capsule. Control samples showed a negative difference between the kidney’s and the graft’s 
regular blood flow of -34.5 % (95% confidence interval -41; -28). Importantly, the difference 
in blood flow in sitagliptin-treated mice was significantly lower -9.7 % (95% confidence 
interval -16; -2; p < 0.01) (Figure 11).  
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Figure 4-11: DPP-IV inhibition increases functional blood flow to transplanted islets. 
Blood flow measured by Doppler ultrasound probe simultaneously on the kidney capsule 
surface and at the site of the grafted islets. The difference (%) of kidney and graft blood 
flow is plotted on the ordinate (p < 0.01; n= 6). Data represent mean ± SEM. 
  
Taken together, these data demonstrate that sitagliptin enhances functional vascularization of 
transplanted pancreatic islets. Interestingly, gene expression analysis suggests that the VEGF 
signaling pathway is modulated by sitagliptin treatment (HIF-1α, ARNT, VEGF-A, VEGF-
R2) (Figure 12A to D). 
 
  
Figure 4-12: VEGF signaling pathway is modulated by sitagliptin treatment. (A to D) 
Human islet grafts were retrieved from NMRI-nu/nu mice fed with either 5.5% sitagliptin  or 
normal chow one day or fourteen days after transplantation (Tx). After RNA isolation and 
cDNA synthesis the relative expression of the indicated genes  was quantified by real 
time PCR in triplicates. The effects of different stimulations on individual gene expression 
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were calculated and normalized to endogenous reference gene GAPDH using comparative 
ΔΔCT method (* p<0.05, ** p<0.001). 
 
4.9 Sitagliptin increases VEGF secretion in vitro 
Local blood perfusion is important for regular function and β-cell survival in islet grafts(115; 
116). Since sitagliptin improved re-vascularization, we wondered whether it actually increases 
the VEGF secretion in vitro from islets. For this purpose we treated isolated islets with Glp-1 
(7-36) and analyzed the cell culture supernatants for VEGF secretion. Treatment with Glp-1 
(7-36) but not Glp-1 (9-36) resulted in a significant increase of VEGF release from normal 
islets (Figure 13). Sitagliptin further enhanced the effect of Glp-1 (7-36) resulting in a 4-fold 
increase of VEGF. The use of RIP-VEGF islets demonstrated that VEGF was released from 
the pancreatic β-cells (Figure 13).  
 
Figure 4-13: DPP-IV/Glp-1 regulates secretion of VEGF by β-cells. Mouse islets were 
cultured free floating in Parkers FCS medium in the presence of Glp-1 (7-36), Glp-1 (9-36), 
or sitagliptin. RIP-VEGF islets = islets isolated from mice synthesizing human 
VEGFA165 under the control of the rat insulin promoter (RIP). After 24 h of incubation 
the content of VEGF in the supernatant was determined. Glp-1 (7-36) resulted in higher 
VEGF content of the supernatant than without the presence of Glp-1 (7-36). Islets 
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cultivated in the presence of Glp-1 (7-36) and 5 µM sitagliptin released even more 
VEGF (normal islets * p < 0.05 and RIP-VEGF islets ** p < 0.01) compared to islets 
incubated with Glp-1 (7-36) alone. Data represent mean ± SEM. 
  
These islets were derived from a mouse strain producing VEGF under the control of rat 
insulin promoter as described before(109). The result suggests that sitagliptin induces release 
of VEGF from islets. Next we investigated whether the release of VEGF increases any growth 
or proliferation of islet endothelial cells in vitro. 
4.10 Sitagliptin enhances islet endothelial cell sprouting 
An earlier study demonstrated that VEGF-A controls angiogenic sprouting in the early 
postnatal retina(117). To analyze whether the release of VEGF increases sprouting of islet 
endothelial cells, we isolated islets and studied the effect of sitagliptin on islet endothelial 
cell sprouting into fibrin gels. Interestingly, DPP-IV activity was nearly 30-fold higher in 
islets compared to mouse plasma (6126 ± 320 µmol/min/mg protein vs. 215 ± 18 
µmol/min/mg, p < 0.0001). The addition of bFGF induced low levels of sprouting, which 
was greatly enhanced by VEGF. The addition of Glp-1 (7-36) but not addition of inactive 
Glp-1 (9-36) enhanced the effect of bFGF. Sitagliptin is an inhibitor of DPP-IV that 
cleaves Glp-1 (7-36) to Glp-1 (9-36). As DPP-IV activity was abundant in our assay we 
tested whether addition of sitagliptin to bFGF + Glp-1 (7-36) can further enhance sprouting. 
This combination resulted in an even greater sprouting activity as bFGF + VEGF (Figure 14 
A,B). Taken together these data suggest that sitagliptin enhances VEGF release and thereby 
increases islet endothelial cell proliferation necessary for functional viability of transplanted 
islets by modulating DPP-IV/Glp-1. 
 Next we worked on the mechanism that promoted VEGF secretion and maintained 
functional viability of transplanted islets in vivo. 
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Figure 4-14: Sitagliptin enhances islet endothelial cell sprouting. Analysis of the effect of 
different factors regarding their capacity to induce islet sprouting. bFGF = 5 ng/ml 
human basicfibroblast growth factor, VEGF = 5 ng/ml human vascular endothelial growth 
factor 165, Glp-1 = 50 nM Glucagon-like peptide 1; either the 7-36 peptide or 50 nM 9-36 
fragment. Glp-1 (7-36) is cleaved by dipeptidyl peptidase IV (DPP-IV) resulting in Glp-1 (9-
36), sitagliptin = 5 µM sitagliptin. All data represent mean ± SEM and significance was tested 
using ANOVA with a Bonferroni post hoc test where ** represents p < 0.01 for the 
percentage of sprouting islets in the presence of bFGF and Glp-1 (7-36) versus bFGF, Glp-
1(7-36) and DPP-IV inhibitor sitagliptin demonstrating an additional effect on endothelial 
sprouting by DPP-IV inhibition. (B) Representative pictures of sprout-like structures 
emerging from islets into the fibrin gel due to endothelial proliferation of resident islet 
endothelial cells. 
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 4.11 Sitagliptin improves secretion of VEGF in transplanted islets 
Since sitagliptin treatment improved transplantation outcome and moreover enhanced VEGF 
secretion, thereby increasing the sprouting capacity of isolated islets, we examined VEGF 
secretion from transplanted islets, which will lead to proliferation of host vascular endothelial 
cells(118). For this purpose grafts were retrieved and analyzed for the presence of VEGF 
protein by immunohistochemistry using anti-VEGF antibody. Sitagliptin treatment 
significantly (p < 0.05) increased the total VEGF expression compared to control (Figure 15). 
VEGF is essential for vasculogenesis- de novo formation of blood vessels(118) and our data 
indicate that sitagliptin treatment increases the secretion of VEGF improving vasculogenesis. 
 
  
Figure 4-15: Sitagliptin treatment increases VEGF Expression. Sections were treated with 
Insulin and VEGF antibodies at 4°C overnight and then treated with secondary antibodies. 
The image was captured using Leica fluorescent microscope and analyzed using image J 
software. VEGF staining was more pronounced in the sitagliptin treated group compared to 
the control. The area showing VEGF staining was significantly (p < 0.05) increased in the 
sitagliptin group as represented by their respective bar graphs. n = 4; Data represents mean ± 
SEM. 
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4.12 Sitagliptin sensitizes VEGFR2 in transplanted islets 
VEGF exerts its proangiogenic action by binding to VEGFR-2(119). To assess this, graft 
sections were analyzed for VEGFR2 expression using anti-VEGFR-2 antibody. We found 
that sitagliptin treatment significantly (p < 0.05) increased VEGFR-2 expression within the 
transplanted islets (Figure 16). This result indicates that the proangiogenic action of VEGF 
was further promoted by sensitization of VEGFR-2. 
 
  
Figure 4-16: Proangiogenic action of VEGF is augmented by VEGFR-2 sensitization. 
Sections were treated with Insulin and VEGFR-2 antibodies at 4°C overnight and then 
treated with secondary antibodies. The image was captured using Leica fluorescent 
microscope and analyzed using image J software.  VEGFR-2 staining was more pronounced 
in the sitagliptin treated group compared to the control. The area showing VEGFR-2 staining 
was significantly (p < 0.05) increased in the sitagliptin group as represented by their 
respective bar graphs. n = 4; Data represents mean ± SEM. 
 4.13 Sitagliptin activates CREB pathway  
An earlier study reported that Glp-1 receptor agonists activate CREB and Insulin Receptor 
Substrate (IRS)-2, thereby promoting β-cell growth and survival(120). Similarly, a recent 
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report suggested that the protective role of VEGF-A on neurons and vascular endothelial 
cells is by CREB phosphorylation through VEGFR-2/ERK signaling(121). This prompted us 
to explore whether sitagliptin increases islet vascularization via CREB phosphorylation and 
VEFG/VEGFR-2 signaling. We retrieved kidney grafts and analyzed them for the activation 
of CREB by immunocytochemistry. Sitagliptin treatment enhanced CREB expression and 
phosphorylation compared to control. The number of nuclei with translocated CREB protein 
was significantly (p < 0.01) increased in the sitagliptin-treated group (Figure 17 A, B). 
These results indicate that DPP-IV inhibition induces vasculogenesis of transplanted islets by 
VEGF secretion through phosphorylation of CREB in transplanted β-cells. 
 
  
Figure 4-17: Sitagliptin phosphorylates CREB and aids in revascularization of islet 
grafts. Sections were treated with Insulin, CREB and pCREB antibodies at 4°C overnight 
and then treated with secondary antibodies. The image was captured using Leica fluorescent 
microscope and analysed using image J software. CREB (A) and pCREB (B) staining was 
more pronounced in the sitagliptin treated group compared to the control. The number of 
nuclei stained positive for CREB (A) and pCREB (B) was significantly (p < 0.01) increased 
in the sitagliptin group as represented by their respective bar graphs. n = 4; Data represents 
mean ± SEM. 
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4.14 Sitagliptin enhances mTOR and P70S6K expression 
Since DPP-IV inhibition activated CREB in transplanted islets, we next studied the 
mTOR/P70S6K pathway that will lead to the cell growth and proliferation(122). For this we 
retrieved kidney grafts and analyzed them for the expression of pMTOR and P70S6K. 
Sitagliptin treatment increased the expression of pMTOR and P70S6K as evidenced by 
immunohistochemistry (Figure 18A, B). 
  
Figure 4-18: Sitagliptin phosphorylates mTOR and activates P70S6K. Sections were 
treated with Insulin, pMTOR (A) and P70S6K (B) antibodies at 4°C overnight and then 
treated with secondary antibodies. The image was captured using Leica fluorescent 
microscope. 
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5.Discussion 
Sitagliptin is considered to enhance active GLP-1 levels by suppressing proteolytic DPP-IV 
activity resulting in increased β -cell survival in rodent models of diabetes and islet 
transplantation(112; 123-125). On the other hand, it has been demonstrated that the efficiency 
of pancreatic islet transplantation depends on re-vascularization. Therefore, we have 
investigated mechanisms underlying the effect of sitagliptin on partial pancreatectomy and 
pancreatic islet transplantation with focus on angiogenesis. Our data suggest that sitagliptin 
accelerates normalization of the blood glucose level in a diabetes model by stabilizing GLP-1, 
which in turn results in increased insulin production due to an increase in β-cell mass, VEGF 
expression and vascularization. 
5.1 Sitagliptin promotes β-cell proliferation and insulin area in partial pancreatectomy 
Partial pancreatectomy is the most commonly used model for the study of β-cell 
regeneration(126). Experimental evidence indicate that the β-cells were derived from 
preexisting islets rather than islet neogenesis(126). Our data suggest that the number of BrdU 
and insulin positive cells was significantly increased with sitagliptin treatment in partial 
pancreatectomised mice. Moreover, the insulin area was also significantly increased after 
sitagliptin treatment. There are controversies regarding the cellular origin of β-cell 
replication. In particular, the ductal progenitor hypothesis remains debated vigorously(51). 
Lineage tracing studies indicate that specialized progenitors do not contribute to adult β-cells, 
not even during acute β-cell regeneration after injury, but β-cells are the products of uniform 
self- renewal(127). The cell lineage tracing experiments show compelling evidence that 
pancreatic ductal epithelium does not contribute to β-cell growth during acute regeneration 
but may have originated from a source other than ductal epithelium(128). Our data suggest 
that sitagliptin improves the diabetic outcome by inhibiting DPP-IV activity and 
concentration. It also increased the number of BrdU positive β-cells and ductal cells and 
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insulin area in pancreatic sections. However, we cannot decide from our experiments whether 
ductal cells or β-cells are the main source of proliferation and enlarged insulin area. 
5.2 The DPP-IV-Glp-1-VEGF axis 
Pancreatic islets are highly vascularized and formation of their microvessels depends on the 
expression of VEGF in β -cells(129). Endothelial cells and microvessels are needed for 
coordinated insulin secretion of hundreds of β -cells within pancreatic islet(124; 125). Our 
results show that sitagliptin treatment increased the number of proliferating endothelial cells 
and also the area occupied by endothelial cells, indicating that actual vascularization takes 
place after islet transplantation. Studies in mutant mice with pancreas specific expression of 
VEGF in pancreatic islets have supported the idea of an association between the vascular 
system and β -cell mass. There is experimental evidence not only in pancreatic islet 
transplantation(129; 130) but also for streptozotocin-induced diabetes(92) and 
pregnancy(131). While endogenous VEGF released from grafted pancreatic islets was 
beneficial for transplantation outcome, prolonged pharmaceutical administration resulted in 
decreased islet functionality(132) and microvascular leakage(133). However, no link between 
GLP-1 receptor activation and VEGF release has been described so far. 
Our data show that DPP-IV was highly active in islets isolated with collagenase. 
Inhibition of DPP-IV by sitagliptin accelerated normalization of the blood glucose level in a 
diabetes model by stabilizing GLP-1. This phenomenon correlated with enhanced insulin 
production due to an increase in β-cell mass. Interestingly, sitagliptin treatment also resulted 
in an increased expression of VEGF, improved vascularization and functional blood flow to 
the graft. This correlation in vivo raises the question whether vascularization is a direct or 
indirect effect of sitagliptin treatment. Sitagliptin treatment inhibits DPP-IV, which is known 
to cleave the hormone Glp-1 (7-36) into its inactive form Glp-1 (9-36). Glp-1 is secreted from 
the gut and has several functions including the regulation of insulin production(134). Our 
finding that VEGF secretion and endothelial cell sprouting is enhanced by inhibition of DPP-
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IV in the presence of Glp-1 (7-36), but not in the presence of the cleavage product Glp-1 (9-
36) indicates that the DPP-IV regulates VEGF expression via stabilization of Glp-1. Our data 
furthermore suggest that this axis controls both local and systemic availability of VEGF 
necessary for vascularization.  
Our in vitro data demonstrated that Glp-1 alone significantly increased VEGF release 
from pancreatic islets. It is possible that in vivo DPP-IV inhibition activated additional pro-
angiogenic pathways. There is not only cell membrane abundant peptidase but also a 
catalytically active soluble form. Basically, the enzyme would cleave dipeptides from all 
proteins with proline in the penultimate position, however in vivo proteolysis could be 
affected by modulating factors, for example glycation of the catalytic site due to 
hyperglycemia in models of diabetes(135). DPP-IV is believed to primarily modulate the 
availability of GLP-1, but other peptides cleaved by DPP-IV, such as GLP-2 or vasoactive 
peptide(136) could be involved. Chemical inhibition of DPP-IV was reported to reduce 
attraction of leukocytes in a T-lymphocyte induced immune response(137). However, 
recruitment of CD11b+ immune cells into the transplantation site was not different between 
treated and control in our model.  
5.3 Potential intracellular links between GLP-1 receptor activation and VEGF synthesis in 
the β-cell 
Islet cells are avascular after islet isolation and reduced islet vascularity immediately after 
islet transplantation contributes to the early loss of islets and its function(93).The classical 
activation of VEGF transcription is regulated by HIF-1α when oxygen concentrations 
decrease. VEGF synthesis can also be regulated by genetic rather than hypoxia-induced HIF-
1α activation(138). In our study we observed increased gene expression of HIF-1α and 
ARNT. It was reported that the CREB binding protein (CBP), which in turn was activated by 
GLP-1 via the cAMP and Protein Kinase A pathway(139) had a stabilizing effect on the 
formation of the complex between HIF-1α and its DNA-binding partner, ARNT(140). Our 
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findings also showed an increased expression of PGC-1α mRNA levels, which is up regulated 
in proliferating islets(139) and increases VEGF synthesis through Estrogen-related Receptor-
α.(102). Thus based on our data we suggest that the main mechanism of VEGF expression is 
GLP-1 stabilization by inhibition of DPP-IV through sitagliptin under conditions of 
pancreatic islet transplantation. The observed increase in proliferative activity of both β-cells 
and endothelial cells by DPP IV inhibition is attributed to the increase in the VEGF induced 
cell proliferation mediated by GLP-1. 
5.4 Glp-1 receptor activation, CREB phosphorylation, mTOR activation and VEGF 
synthesis in β-cells by DPP-IV inhibition    
The vascularization of islets could be increased by several interventions. One approach 
could be by increasing the proangiogenic factors responsible for formation, proliferation and 
maturation of islet endothelial cells into fully functional islet vasculature(89). This approach 
was demonstrated to increase functional islet mass by improving the angiogenesis of isolated 
porcine and murine islets(109). In our study we chose to inhibit DPP-IV so that the available 
Glp-1 could be used for activation of VEGF, thereby inducing vascularization of transplanted 
islets. VEGF is required for vasculogenesis(118) and our data demonstrate that sitagliptin 
treatment increased VEGF expression in transplanted islets. Moreover, experimental evidence 
suggests that the observed vascular endothelial cell response of VEGF was mediated by 
VEGFR-2(118). Our data shows that sitagliptin treatment enhanced the expression of 
VEGFR-2 in transplanted islets further supporting vascularization. 
Interestingly, Glp-1R agonists activate CREB and Insulin Receptor Substrate (IRS)-2, 
promoting β-cell growth and survival(120). Also a recent finding suggests that mTOR is 
linked to the incretin signaling to HIF induction, promoting pancreatic islet viability(141). 
Similarly the protective role of VEGF-A on neurons and vascular endothelial cells is by 
phosphorylation of CREB through VEGFR-2/ERK signaling(121). Our data show that 
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sitagliptin treatment induced phosphorylation of CREB resulting in its activation of the 
VEGF-A/VEGFR-2 signaling pathway. 
Thus we conclude that the main mechanism of VEGF expression and islet 
vascularization is Glp-1 stabilization by DPP-IV inhibition through sitagliptin followed by 
Glp-1R activation leading to phosphorylation of CREB and activation of mTOR, which in 
turn modulates VEGF-A/VEGFR-2 signaling thereby increasing the vascularization of 
transplanted islets. The observed increase in proliferative activity of both β-cells and 
endothelial cells by DPP-IV inhibition is attributed to activation of P70S6K mediated by 
increased availability of Glp-1(Figure 19). 
  
 
Figure 5-19: Model of CREB, mTOR and P70S6K activation and the VEGF-A/VEGFR-2 
pathway regulating secretion of VEGF by DPP-IV inhibition in β-cells.   
  
Taken together, we have discovered a new pathway by which sitagliptin improves 
vascularization of transplanted mouse, porcine and human islets. From a therapeutic 
perspective this mechanism could open new venues to prevent the decline of insulin secreting 
capacity in in pancreatic islet transplantation. 
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